IP Verse

Alnylam Pharmaceuticals, Inc. opposition analysis

COMPANY ANALYSIS

Latest oppositions filed by Alnylam Pharmaceuticals, Inc.

Patent Number:
EP2978451
Title:
Compositions And Methods For Increasing The Serum Half-Life Of A Therapeutic Agent Targeting Complement C5
Applicant:
ALEXION PHARMACEUTICALS, INC.
Opposition Date:
Aug 27, 2020
Patent Number:
EP1857547
Title:
Further Novel Forms Of Interfering Rna Molecules
Applicant:
ATUGEN AG
Opposition Date:
Aug 17, 2018

Latest patents of Alnylam Pharmaceuticals, Inc. opposed by its competitors

Patent:
EP3366775
Grant Date:
Apr 27, 2022
Title:
Modified Rnai Agents
Oppositions:
1
Patent:
EP3656860
Grant Date:
Apr 20, 2022
Title:
Angiopoietin-Like 3 (Angptl3) Irna Compositions And Methods Of Use Thereof
Oppositions:
1
Patent:
EP3105331
Grant Date:
Jun 23, 2021
Title:
Ketohexokinase (Khk) Irna Compositions And Methods Of Use Thereof
Oppositions:
1
Patent:
EP2723758
Grant Date:
Jun 20, 2018
Title:
Angiopoietin-Like 3 (Angptl3) Irna Compostions And Methods Of Use Thereof
Oppositions:
1

Competitors of Alnylam Pharmaceuticals, Inc.

GRUNECKER PATENT- UND RECHTSANWALTE PARTG MBB

ALEXION PHARMACEUTICALS, INC.

ATUGEN AG

Want to track Alnylam Pharmaceuticals, Inc.?

Feel free to send us a message here and we will get back to you